Option chain shows key data for Acrivon Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Acrivon Therapeutics.

Acrivon Therapeutics (NASDAQ:ACRV) Stock, Option Chain

ACRIVON THERAPEUTICS INC

Acrivon Therapeutics

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.

Trade tensions weigh on oil demand

Earnings

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

ACON

ACRV

CTAS

OSRH

VVPR

Crude Oil Gains Over 1%; Cintas Shares Jump After Q3 Earnings

The Drop In Nasdaq

DLTR

PTPI

Nasdaq Down 1%; Dollar Tree To Sell Family Dollar Business For $1 Billion

Biotech

Earnings Beats

Penny Stocks

Small Cap

Analyst Ratings

General

ADPT

ATHA

RAPT

Athira Pharma, Inc (NASDAQ: ATHA) recently announced that it has dosed the last patient in the phase II/III LIFT-AD study, which is evaluating its pipeline candidate, fosgonimeton for the treatment of mild-to-moderate Alzheimer&#39;s disease (AD).

Athira Completes Dosing in Alzheimer&#39;s Study, Stock Up

Acrivon Therapeutics, Inc. - Common Stock

Acrivon Therapeutics Inc

Health Care

Press Releases

Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity

Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Acrivon Therapeutics to Present Data Demonstrating Deployment of its AP3 Platform for Streamlined Drug Discovery and Clinical Development at Two Scientific Conferences - Human Proteome Organization World Congress and EORTC-NCI-AACR Symposium

Acrivon Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights

Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer

Acrivon Therapeutics to Host Corporate R&D Event to Provide AP3 Platform Capabilities and Clinical ACR-368 and ACR-2316 Program Updates

Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results

Management

Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer

Acrivon Therapeutics to Reveal the Molecular Mechanisms Driving Strong Single-Agent Activity of ACR-2316, its AP3-Enabled Clinical Stage WEE1/PKMYT1 Inhibitor, at the AACR Annual Meeting 2025

Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights

Comments

Acrivon Therapeutics

Acrivon Therapeutics (ACRV) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell